Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy

Nonalcoholic fatty liver disease (NAFLD) has become globally prevalent and is the leading cause of chronic liver disease. Although NAFLD is reversible without medical intervention in the early stage, the condition could be sequentially worsened to nonalcoholic steatohepatitis (NASH) and, eventually,...

Descripción completa

Detalles Bibliográficos
Autores principales: Amatya, Reeju, Lee, Donghee, Min, Kyoung Ah, Shin, Meong Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386216/
https://www.ncbi.nlm.nih.gov/pubmed/37514148
http://dx.doi.org/10.3390/pharmaceutics15071963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386216/
https://www.ncbi.nlm.nih.gov/pubmed/37514148
http://dx.doi.org/10.3390/pharmaceutics15071963

Ejemplares similares